| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|
Catabasis Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy.
Ticker: CATB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1454789
Employees: 27
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Can't Get My Head Around Catabasis Pharmaceuticals
17th February 2021